Effects of dexmedetomidine on hemodynamic, oxygenation, microcirculation, and inflammatory markers in a porcine model of sepsis

Purpose: To determine whether dexmedetomidine aggravates hemodynamic, metabolic variables, inflammatory markers, and microcirculation in experimental septic shock. Methods: Twenty-four pigs randomized into: Sham group (n = 8), received saline; Shock group (n = 8), received an intravenous infusion of Escherichia coli O55 (3 × 109 cells/mL, 0.75 mL/kg, 1 hour); Dex-Shock group (n = 8), received bacteria and intravenous dexmedetomidine (bolus 0.5 mcg/kg followed by 0.7 mcg/kg/h). Fluid therapy and/ornorepinephrine were administered to maintain a mean arterial pressure > 65 mmHg. Hemodynamic, metabolic, oxygenation, inflammatory markers, and microcirculation were assessed at baseline, at the end of bacterial infusion, and after 60, 120, 180, and 240 minutes. Results: Compared to Shock group, Dex-Shock group presented a significantly increased oxygen extraction ratio at T180 (23.1 ± 9.7 vs. 32.5 ± 9.2%, P = 0.0220), decreased central venous pressure at T120 (11.6 ± 1 vs. 9.61 ± 1.2 mmHg, P = 0.0214), mixed-venous oxygen saturation at T180 (72.9 ± 9.6 vs. 63.5 ± 9.2%, P = 0.026), and increased plasma lactate (3.7 ± 0.5 vs. 5.5 ± 1 mmol/L, P = 0.003). Despite the Dex-Shock group having a better sublingual vessel density at T240 (12.5 ± 0.4 vs. 14.4 ± 0.3 mL/m2; P = 0.0003), sublingual blood flow was not different from that in the Shock group (2.4 ± 0.2 vs. 2.4 ± 0.1 mL/kg, P = 0.4418). Conclusions: Dexmedetomidine did not worsen the hemodynamic, metabolic, inflammatory, or sublingual blood flow disorders resulting from septic shock. Despite inducing a better sublingual vessel density, dexmedetomidine initially and transitorily increased the mismatch between oxygen supply and demand.

Evidence of cytogenetic and histological damage in specimens of Astyanax lacustris (Pisces, Characidae) exposed to the hydrogen cyanide-based herbicide Dormex®

The herbicide Dormex®, a solution of hydrogen cyanamide, is a growth regulator capable of breaking the dormancy of fruit plants, and is commonly applied in agriculture. However, the biological effects of this product on non-target organisms are unknown. The present study investigated the biological response of Astyanax lacustris (Lütken, 1875) specimens exposed to Dormex® using a chromosome aberration test, the mitotic index, and the histological analysis of the gills. Forty specimens of Astyanax lacustris were obtained from a local breeding facility and divided into 10 groups (nine experimental and one control) with four fish in each aquarium (group). The control group was maintained for 24 hours in dechlorinated water while the experimental groups were allocated to one of nine different treatments, with three concentrations of Dormex®, 0.05, 0.1 and 0.5 mL L-1, and exposure for 24, 48 and 72 hours. The fish exposed to Dormex® presented chromosomal aberrations of a number of types, including chromosomal breaks, acentric fragments, decondensation, and gaps at the three Dormex® concentrations, at all exposure times. The mitotic index decreased significantly in comparison with the control group. The histological preparations of the gills revealed alterations such as hyperplasia, and lamellar fusion and edema, whereas in the control group the structure of the gills was preserved. The cytogenetic analysis revealed the genotoxic potential of the herbicide Dormex® and the morphological alterations of the gills demonstrated the sensitivity of the fish, which responded rapidly to the stressor. These findings reinforce the need for special care and restrictions on the use of these herbicides in agricultural areas located near aquatic environments.

Evidence of cytogenetic and histological damage in specimens of Astyanax lacustris (Pisces, Characidae) exposed to the hydrogen cyanide-based herbicide Dormex®

The herbicide Dormex®, a solution of hydrogen cyanamide, is a growth regulator capable of breaking the dormancy of fruit plants, and is commonly applied in agriculture. However, the biological effects of this product on non-target organisms are unknown. The present study investigated the biological response of Astyanax lacustris (Lütken, 1875) specimens exposed to Dormex® using a chromosome aberration test, the mitotic index, and the histological analysis of the gills. Forty specimens of Astyanax lacustris were obtained from a local breeding facility and divided into 10 groups (nine experimental and one control) with four fish in each aquarium (group). The control group was maintained for 24 hours in dechlorinated water while the experimental groups were allocated to one of nine different treatments, with three concentrations of Dormex®, 0.05, 0.1 and 0.5 mL L-1, and exposure for 24, 48 and 72 hours. The fish exposed to Dormex® presented chromosomal aberrations of a number of types, including chromosomal breaks, acentric fragments, decondensation, and gaps at the three Dormex® concentrations, at all exposure times. The mitotic index decreased significantly in comparison with the control group. The histological preparations of the gills revealed alterations such as hyperplasia, and lamellar fusion and edema, whereas in the control group the structure of the gills was preserved. The cytogenetic analysis revealed the genotoxic potential of the herbicide Dormex® and the morphological alterations of the gills demonstrated the sensitivity of the fish, which responded rapidly to the stressor. These findings reinforce the need for special care and restrictions on the use of these herbicides in agricultural areas located near aquatic environments.(AU)

Effect of allopurinol on the kidney function, histology and injury biomarker (NGAL, IL 18) levels in uninephrectomised rats subjected to ischaemia-reperfusion injury

PURPOSE: To investigate whether allopurinol exerts a protective effect on kidneys by measuring new kidney injury biomarkers (NGALp, NGALu, KIM 1 and IL 18) and analysing the renal function and histology in uninephrectomised rats subjected to ischaemia-reperfusion injury. METHODS: Thirty two Wistar rats were randomly allocated to four groups: Sham (S): laparotomy; Control (C): laparotomy and ischaemia-reperfusion in the left kidney; Control Allopurinol (CA): laparotomy and allopurinol at a dose of 100mg·kg 1·d 1; and Allopurinol (A): laparotomy ischaemia-reperfusion in the left kidney and allopurinol at a dose of 100mg·kg 1·d 1. The NGALp, NGALu, KIM 1, IL 18 and creatinine levels and the kidney histology were analysed. The significance level was established as p<0.05. RESULTS: Creatinine level increased in all the groups, with A ≈ C > S ≈ CA. The NGALp, NGALu and IL 18 levels exhibited similar behaviour in all the groups. KIM 1 was higher in group A than C and showed intermediate values in groups S and CA. Severity of injury in the left kidney was greater in groups C and A compared to S and CA. CONCLUSION: Allopurinol did not exert protective or damaging effects on the kidneys of rats subjected to ischaemia-reperfusion injury.(AU)

Óxido nítrico, GSTP-1 e p53: qual o papel desses biomarcadores nas lesões prostáticas do cão? / Nitric oxide, GSTP-1 and p53: what's the role of these biomarkers in dogïs prostate lesions?

Confeccionou-se um microarranjo de tecido (TMA) com 146 amostras de lesões prostáticas caninas. Este continha 17,2 por cento de hiperplasia prostática benigna (HPB), 32,4 por cento de atrofia inflamatória proliferativa (PIA), 2,6 por cento de prostatite, 8,6 por cento de focos de neoplasia intraepitelial prostática (PIN), 29,1 por cento de carcinomas e 9,3 por cento de próstatas normais. Cortes histológicos sequenciais foram feitos e utilizados para reação de imunoistoquímica com os anticorpos primários anti-p-53, anti-NOS-2 e anti-GSTP. Avaliou-se de cada core o escore de células marcadas para cada anticorpo utilizado. Os resultados foram tabulados por grupo diagnóstico e submetidos ao teste Tuckey. Os carcinomas prostáticos do cão e a PIA apresentaram maior número de amostras (41) com mais de 75 por cento das células positivas para NOS-2, demonstrando a influência do estresse oxidativo no desenvolvimento dessas lesões. As próstatas normais e as afecções desta glândula, HPB, PIA, PIN, prostatite e carcinoma, expressaram a proteína GSTP-1, o que conferiu proteção ao tecido prostático canino a danos oxidativos. A proteína p53 estava presente em todas as amostras estudadas, incluindo o tecido prostático normal, porém as lesões prostáticas apresentaram maior número de amostras com escores mais elevados de marcação (escores três e quatro), presente em 95 por cento dos focos de PIA e carcinoma. Concluiu-se que o aumento de expressão de óxido nítrico nas lesões prostáticas no cão e a expressão de GSTP-1 podem ter protegido o tecido prostático canino e que a expressão de p53 foi positiva e uniforme nas próstatas normais e com lesões hiperplásicas e displásicas.(AU)

A tissue microarray (TMA) with 149 samples of canine prostatic lesions contained 17.2 percent benign prostatic hyperplasia (BPH), 32.4 percent proliferative inflammatory atrophy (PIA), 2.6 percent prostatitis, 8.6 percent foci prostatic intraepithelial neoplasia (PIN), 29.1 percent carcinomas and 9.3 percent normal prostates. Sequential histological sections were made and used for immunohistochemistry reaction with primary antibodies anti p-53, anti-NOS-2 and anti-GSTP. The score for each antibody employed was evaluated. The results were tabulated by diagnostic group and subjected to Tuckey test. Prostatic carcinomas and PIA had a higher number of samples (41) with over 75 percent of cells positive for NOS-2, demonstrating the influence of oxidative stress in the development of these lesions. The prostates of normal dogs, as well as the disorders of this gland (BPH, PIA, PIN, prostatitis and carcinoma), expressed GSTP-1 protein, which gives protection to the canine prostate tissue against oxidative damage. The p53 protein was present in all samples studied, including normal prostate tissue, but the prostatic lesions had a higher number of samples with higher scores (more than 50 percent of positive cells), in 95 percent of foci of PIA and carcinoma. It was found that an increased expression of NO in prostatic lesions of dogs and that the expression of GSTP-1 can protect the canine prostate tissue, which would contribute to the low frequency of prostate adenocarcinoma in this species. The expression of p53 was positive in all lesions as well as the in normal prostate.(AU)

Determinação de produtos de biotransformação de aflotoxina B1 e aplicabilidade na avaliação da eficiência de um adsorvente à base de aluminossilicato de cálcio e sódio hidratado em frangos de corte / Determination of aflatoxin B1 biotransformation products and applicability for the efficacy evaluation of a hydrated sodium calcium aluminosilicate-based adsorbent in broiler chicks

O objetivo do presente trabalho foi determinar resíduos de aflatoxinas M1 (AFM1), aflatoxicol (AFL), B1 (AFB1), B2 (AFB2), G1 (AFG1) e G2 (AFG2) não metabolizadas no fígado e rim de frangos de corte, com a finalidade de verificar sua aplicabilidade na avaliação da eficiência de um adsorvente comercial à base de aluminossilicato de cálcio e sódio (HSCAS) incorporado na dieta, bem como determinar o percentual de ligação do adsorvente com a AFB1em ensaios in vitro. Cem frangos de corte (Ross 708), machos, de 1 dia de idade, foram mantidos em baterias metálicas, com acesso ad libitum à ração e água. Utilizou-se um delineamento inteiramente casualizado com 4 tratamentos, sendo cada tratamento composto por 5 gaiolas contendo 5 frangos em cada uma. Os tratamentos foram os seguintes: A) dieta basal (DB), sem adição de HSCAS ou AFB1; B) DB com adição de 0,5% de HSCAS; C) DB com adição de 2,5 mg/kg de AFB1; e D) DB com adição de 2,5 mg/kg de AFB1 e 0,5% de HSCAS. As rações experimentais foram administradas de 1 a 21 dias de vida. No dia 21, 5 frangos de cada tratamento foram insensibilizados com dióxido de carbono, mortos por deslocamento cervical e amostras de fígado e rim foram coletadas para análise de resíduos de AFB1. O HSCAS foi efetivo em se ligar, in vitro, à AFB1, cujos percentuais de ligação variaram de 8,8 a 99,5%, para concentrações do adsorvente entre 0,05 e 100 mg/10 mL.

The objective of the study was to determine residues of aflatoxin M1 (AFM1), aflatoxicol (AFL), B1 (AFB1), B2 (AFB2), G1 (AFG1) and G2 (AFG2) non-metabolized in liver and kidney of broiler chicks, aiming to verify its applicability for evaluation of a commercial adsorbent based-HSCAS efficacy incorporated into the diet, aswell as to determine the binding capacity of a HSCAS for AFB1 in an in vitro testing. One hundred day-old male broilers (Ross 708) were maintained in chick batteries and allowed libitum access to feed and water. A completely randomized design was used with 5 replicate pens of5 chicks assigned to each of 4 dietary treatments from hatch to 21 days. Dietary treatments included: A) basal diet (BD), with no HSCAS or AFB1; B) BD supplemented with 0.5% HSCAS only; C) BD supplemented with 2.5 mg AFB1/kg of feed; and D) BD supplemented with 2.5 mg AFB1/kg of feed and 0.5% HSCAS. On day 21, 5 chicks from each treatment wereinsensibilized with carbon dioxide, killed by cervical dislocation and samples of liverand kidney collected for analysis of AFB1 residues. The HSCAS was effective to binding AFB1 in vitro, with percentage of AFB1 bound varying from 8.8 to 99.5% for adsorbent concentrations between 0.05 and 100 mg/10mL.

Determinação de produtos de biotransformação de aflotoxina B1 e aplicabilidade na avaliação da eficiência de um adsorvente à base de aluminossilicato de cálcio e sódio hidratado em frangos de corte / Determination of aflatoxin B1 biotransformation products and applicability for the efficacy evaluation of a hydrated sodium calcium aluminosilicate-based adsorbent in broiler chicks

O objetivo do presente trabalho foi determinar resíduos de aflatoxinas M1 (AFM1), aflatoxicol (AFL), B1 (AFB1), B2 (AFB2), G1 (AFG1) e G2 (AFG2) não metabolizadas no fígado e rim de frangos de corte, com a finalidade de verificar sua aplicabilidade na avaliação da eficiência de um adsorvente comercial à base de aluminossilicato de cálcio e sódio (HSCAS) incorporado na dieta, bem como determinar o percentual de ligação do adsorvente com a AFB1em ensaios in vitro. Cem frangos de corte (Ross 708), machos, de 1 dia de idade, foram mantidos em baterias metálicas, com acesso ad libitum à ração e água. Utilizou-se um delineamento inteiramente casualizado com 4 tratamentos, sendo cada tratamento composto por 5 gaiolas contendo 5 frangos em cada uma. Os tratamentos foram os seguintes: A) dieta basal (DB), sem adição de HSCAS ou AFB1; B) DB com adição de 0,5% de HSCAS; C) DB com adição de 2,5 mg/kg de AFB1; e D) DB com adição de 2,5 mg/kg de AFB1 e 0,5% de HSCAS. As rações experimentais foram administradas de 1 a 21 dias de vida. No dia 21, 5 frangos de cada tratamento foram insensibilizados com dióxido de carbono, mortos por deslocamento cervical e amostras de fígado e rim foram coletadas para análise de resíduos de AFB1. O HSCAS foi efetivo em se ligar, in vitro, à AFB1, cujos percentuais de ligação variaram de 8,8 a 99,5%, para concentrações do adsorvente entre 0,05 e 100 mg/10 mL. (AU)

The objective of the study was to determine residues of aflatoxin M1 (AFM1), aflatoxicol (AFL), B1 (AFB1), B2 (AFB2), G1 (AFG1) and G2 (AFG2) non-metabolized in liver and kidney of broiler chicks, aiming to verify its applicability for evaluation of a commercial adsorbent based-HSCAS efficacy incorporated into the diet, aswell as to determine the binding capacity of a HSCAS for AFB1 in an in vitro testing. One hundred day-old male broilers (Ross 708) were maintained in chick batteries and allowed libitum access to feed and water. A completely randomized design was used with 5 replicate pens of5 chicks assigned to each of 4 dietary treatments from hatch to 21 days. Dietary treatments included: A) basal diet (BD), with no HSCAS or AFB1; B) BD supplemented with 0.5% HSCAS only; C) BD supplemented with 2.5 mg AFB1/kg of feed; and D) BD supplemented with 2.5 mg AFB1/kg of feed and 0.5% HSCAS. On day 21, 5 chicks from each treatment wereinsensibilized with carbon dioxide, killed by cervical dislocation and samples of liverand kidney collected for analysis of AFB1 residues. The HSCAS was effective to binding AFB1 in vitro, with percentage of AFB1 bound varying from 8.8 to 99.5% for adsorbent concentrations between 0.05 and 100 mg/10mL. (AU)

Determinação de biomarcadores cardíacos em gatos Maine Coon geneticamente testados para a mutação da cardiomiopatia hipertrófica / Cardiac biomarkers in Maine Coon cats genetically tested for hypertrophic cardiomyopathy

A cardiomiopatia hipertrófica (CMH) é a cardiopatia mais diagnosticada em felinos e responsável por morbidade e mortalidade elevadas. A desorganização do sarcômero no miocárdio de gatos afetados com a CMH tem relação com a mutação do gene miosina ligado à proteína C (MYBPC3). A concentração plasmática de biomarcadores cardíacos como o aminoterminal peptídeo natriurético atrial (NTproANP) e o aminoterminal peptídeo natriurético tipo B (NT-proBNP) liberados, respectivamente, secundária ao estresse da parede miocárdica dos átrios e ventrículos; a troponina I cardíaca (cTnI), liberada secundariamente à lesão miocárdica; e a endotelina tipo 1 (ET-1), um peptídeo vasoconstrictor potente cuja concentração plasmática aumenta em pacientes com insuficiência cardíaca, tem incrementado o diagnóstico de cardiopatias em humanos. A CMH é diagnosticada pela ecocardiografia convencional pela evidenciação de hipertrofia cardíaca (HC) segmentar ou difusa. Este estudo utilizou 57 gatos da raça Maine Coon, testados geneticamente para a mutação (M), que foram separados em quatro grupos: GIA com M e com HC (n= 4); GIB com M e sem HC (n= 10); GIIA sem M e com HC (n= 5); GIIB sem M e sem HC (n= 38) e avaliados por meio de ecocardiografia convencional e determinação dos biomarcadores cardíacos NT-proANP, NTproBNP, cTnI e ET-1. A prevalência da mutação nos gatos estudados foi de 24,56%. Diferenças estatísticas significantes foram observadas nos valores de NT-proBNP entre os grupos GIA e GIIB e GIA e GIB; de cTnI entre GIA e GIIB. Quando considerado apenas a presença ou ausência da mutação ou da hipertrofia, foram encontrados valores maiores de NT-proBNP em animais com HC e de cTnI em animais com mutação. Com base na metodologia utilizada, estabeleceu-se um ponto de corte para o NT-proBNP, considerando a presença de hipertrofia de 189,9 pmol/L, com sensibilidade de 77,8%, especificidade de 81,3%, valor preditivo positivo de 43,8% e valor preditivo negativo de 95,1 para o NT-proBNP, e o outro ponto de corte de 0,015 ng/mL, com sensibilidade de 64,3%, especificidade de 81,4%, valor preditivo positivo de 52,9% e valor preditivo negativo de 87,5% para a cTnI. A perspectiva para novos estudos concerne à cTnI e sua relação com a presença da mutação MYBPC3

Hypertrophic cardiomyopathy (HCM) is the most common feline heart disease and is responsible for high morbidity and mortality rates. Sarcomere disorganization in the affected myocardium of cats with HCM is related to the myosin binding protein C (MYBPC3) gene mutation. The plasma concentration of cardiac biomarkers such as atrial aminoterminal natriuretic peptide (NT-proANP) and Type B aminoterminal natriuretic peptide (NT-proBNP) released, respectively, by atrial and ventricular myocardium secondary to wall stress; cardiac troponin I (cTnI), released secondary to myocardial injury; and type 1 endothelin (ET-1), a potent vasoconstrictor peptide have been increasingly used for evaluation of human heart disease which are increased in patients with heart failure (HF). HCM is diagnosed by the presence of segmental or diffuse cardiac hypertrophy (CH) through conventional echocardiography. This study enrolled 57 Maine Coon cats screened for mutation (M) that were assigned to four groups: GIA with M and with CH (n= 4); GIB with M and without CH (n= 10); GIIA without M and with CH (n= 5); GIIB without M and without CH (n= 38) and evaluated by conventional echocardiography and cardiac biomarkers NT-proANP, NT-proBNP, cTnI and ET-1 measurements. The prevalence of the mutation in this study was 24.56%. Statistically significantly differences were observed in NT-proBNP among GIA and GIIB groups and among GIA and GIB groups; and in cTnI between GIA and GIIB groups. When considering only mutation and CH presence or absence, higher values of NT-proBNP were found in CH cats, and higher values of cTnI in those with mutation. Based on proposed methodology, cut-off value to NT-proBNP considering CH presence of 189.9 pmol/L had a sensitivity of 77.8%, specificity of 81.3%, predictive positive value of 43,8% and predictive negative value of 95,1% and the cut-off value of 0.015 ng/mL for cTnI considering mutation presence had a sensitivity of 64.3%, specificity of 81.4%, predictive positive value of 52,9% and predictive negative value of 87,5%. This study opened new perspectives to studies related to cTnI and MYBPC3 mutation

Determinação de biomarcadores cardíacos em gatos Maine Coon geneticamente testados para a mutação da cardiomiopatia hipertrófica / Cardiac biomarkers in Maine Coon cats genetically tested for hypertrophic cardiomyopathy

A cardiomiopatia hipertrófica (CMH) é a cardiopatia mais diagnosticada em felinos e responsável por morbidade e mortalidade elevadas. A desorganização do sarcômero no miocárdio de gatos afetados com a CMH tem relação com a mutação do gene miosina ligado à proteína C (MYBPC3). A concentração plasmática de biomarcadores cardíacos como o aminoterminal peptídeo natriurético atrial (NTproANP) e o aminoterminal peptídeo natriurético tipo B (NT-proBNP) liberados, respectivamente, secundária ao estresse da parede miocárdica dos átrios e ventrículos; a troponina I cardíaca (cTnI), liberada secundariamente à lesão miocárdica; e a endotelina tipo 1 (ET-1), um peptídeo vasoconstrictor potente cuja concentração plasmática aumenta em pacientes com insuficiência cardíaca, tem incrementado o diagnóstico de cardiopatias em humanos. A CMH é diagnosticada pela ecocardiografia convencional pela evidenciação de hipertrofia cardíaca (HC) segmentar ou difusa. Este estudo utilizou 57 gatos da raça Maine Coon, testados geneticamente para a mutação (M), que foram separados em quatro grupos: GIA com M e com HC (n= 4); GIB com M e sem HC (n= 10); GIIA sem M e com HC (n= 5); GIIB sem M e sem HC (n= 38) e avaliados por meio de ecocardiografia convencional e determinação dos biomarcadores cardíacos NT-proANP, NTproBNP, cTnI e ET-1. A prevalência da mutação nos gatos estudados foi de 24,56%. Diferenças estatísticas significantes foram observadas nos valores de NT-proBNP entre os grupos GIA e GIIB e GIA e GIB; de cTnI entre GIA e GIIB. Quando considerado apenas a presença ou ausência da mutação ou da hipertrofia, foram encontrados valores maiores de NT-proBNP em animais com HC e de cTnI em animais com mutação. Com base na metodologia utilizada, estabeleceu-se um ponto de corte para o NT-proBNP, considerando a presença de hipertrofia de 189,9 pmol/L, com sensibilidade de 77,8%, especificidade de 81,3%, valor preditivo positivo de 43,8% e valor preditivo negativo de 95,1 para o NT-proBNP, e o outro ponto de corte de 0,015 ng/mL, com sensibilidade de 64,3%, especificidade de 81,4%, valor preditivo positivo de 52,9% e valor preditivo negativo de 87,5% para a cTnI. A perspectiva para novos estudos concerne à cTnI e sua relação com a presença da mutação MYBPC3 (AU)

Hypertrophic cardiomyopathy (HCM) is the most common feline heart disease and is responsible for high morbidity and mortality rates. Sarcomere disorganization in the affected myocardium of cats with HCM is related to the myosin binding protein C (MYBPC3) gene mutation. The plasma concentration of cardiac biomarkers such as atrial aminoterminal natriuretic peptide (NT-proANP) and Type B aminoterminal natriuretic peptide (NT-proBNP) released, respectively, by atrial and ventricular myocardium secondary to wall stress; cardiac troponin I (cTnI), released secondary to myocardial injury; and type 1 endothelin (ET-1), a potent vasoconstrictor peptide have been increasingly used for evaluation of human heart disease which are increased in patients with heart failure (HF). HCM is diagnosed by the presence of segmental or diffuse cardiac hypertrophy (CH) through conventional echocardiography. This study enrolled 57 Maine Coon cats screened for mutation (M) that were assigned to four groups: GIA with M and with CH (n= 4); GIB with M and without CH (n= 10); GIIA without M and with CH (n= 5); GIIB without M and without CH (n= 38) and evaluated by conventional echocardiography and cardiac biomarkers NT-proANP, NT-proBNP, cTnI and ET-1 measurements. The prevalence of the mutation in this study was 24.56%. Statistically significantly differences were observed in NT-proBNP among GIA and GIIB groups and among GIA and GIB groups; and in cTnI between GIA and GIIB groups. When considering only mutation and CH presence or absence, higher values of NT-proBNP were found in CH cats, and higher values of cTnI in those with mutation. Based on proposed methodology, cut-off value to NT-proBNP considering CH presence of 189.9 pmol/L had a sensitivity of 77.8%, specificity of 81.3%, predictive positive value of 43,8% and predictive negative value of 95,1% and the cut-off value of 0.015 ng/mL for cTnI considering mutation presence had a sensitivity of 64.3%, specificity of 81.4%, predictive positive value of 52,9% and predictive negative value of 87,5%. This study opened new perspectives to studies related to cTnI and MYBPC3 mutation (AU)